Theratechnologies Inc T.TH

Sales

[jeffm34]

Sales last quarter were 14.0M. This quarter improved by 35%.  That's huge!  Will be interesting to see the breakdown of sales.

[qwerty22]

So Egrifta sales have suffered since the switch to F4/pandemic. This Q's number could largely be accounted for if sales of that drug have recovered to historical norms with some small growth in Trogarzo. Yep the breakdown matters.  

[Spartrap]

Well if you remember, management guided that Egrifta sales last quarter were meaningfully impacted by the fact that pharmacists returned their stock of the old formulation en masse (so those had to be reimbursed). They also guided that they expected pharmacists to *stock* the new formulation during 4th quarter with the opposite effect. I don't like to be the cynical guy, but just that could

[scarlet1967]

Or maybe patients stay longer on F4 due to ease of use. CEO mentioned few times patients avoid clinics due to pandemic, Trogarzo has good compliance but it has to be infused at clinics so my take is the growth could be from increased sales of the Egrifta.

[Wino115]

While I don't wish to rain on the parade with the nice sales number, Spatrap is correct. We should be looking at this over the year, not the quarter, to eliminate the volatility caused by F1 to F4.  So it was a year with revenues up 4% -- nice, but really all that represents is the usual 4-5% price increase they tack on.  Plus, we had some higher net revenue Trog sales in there since

[scarlet1967]

I am not sure but my understanding was the price increase usually happens in early spring.

[SPCEO1]

I did not look to see if Palin already corrected you on the sales number for Trogarzo benefitting from the 10% greater take of total sales as he did me sometime back when I made the same error. THTX reports total sales so their sales number does not change, just their profits as a result of the 10% larger share of those total revenues. As for the sales number, I was happy about it as I was

[qwerty22]

So reading backwards on the early Dec PR on the pre-clinical data in multiple cancers. There was some discussion on the 'oddness' of the timing of that PR but it seems it was just to shed light on what was going in (or had just gone in) the IND. Again it probably wouldn't do any harm to have stated that at the time. From what little I understand about all those different cancer types

[SPCEO1]

I think it would be a delta of $600,000 between the two quarters from that since the CFO said on the conference call it negatively impacted sales in Q3 by $300,000 and would improve Q4 sales by the same amount. So, it was defintely something that helped, but was not the main thing.  TH just needs to string together some consistent progress from quarter to quarter on the legacy drug's

[Jack1016]

SPCEO1, did you see significant growth of Trogarzo and Egrifta sales data in last quarter's Bloomberg report? Thanks.

[SPCEO1]

No, both drugs seemed to be weaker, but particularly Egrifta. But we know that data can be misleading. What will be interesting to see are European sales. Did TH Q4 sales benefit from filling the inventory channel in Germany? That seems unlikely given the high price of Trogarzo and Covid, but it could be a factor that boosted sales on a one-time basis. Of course, they will be doing the same

[Spartrap]

I wouldn't be surprised to see the european market quickly overtake the US market. There's no cult of the oral pill around here. Doctors actually tend to prefer IV drugs for serious diseases because it allows a strict control of patient adherence. Maybe not so much for HIV because it's a life long treatment, so convenience is an important factor, but I mean the barrier to acceptance is

[scarlet1967]

Also just about all European countries including the five countries where Trogarzo will be lunched have extensive general health care coverage, THTX might have to initially negotiate the pricing but after that the process is much more simplified compared to US.

[palinc2000]

This is really extraordinary!!!! Paul was referred to as a marketing ace or something similar by the Chairwoman when he was hired ,,,, I was disappointed with the 3 rd Quarter sales but elated at the 4 th Quarer sales,,,, in spite of the pandemic ,,.... I am hoping for continued progress on that front